Patent Number: 6,251,929

Title: Therapeutic agent for intractable vasculitis

Abstract: A highly safe therapeutic agent for intractable vasculitis such as malignant rheumatoid arthritis contains a hydantoin derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof as an effective ingredient: ##STR1## wherein each of R.sub.1, and R.sub.2, which may be the same or different, represents hydrogen, an alkyl group or a cycloalkyl group; and each of X and Y, which may be the same or different, represents hydrogen, a hydroxyl group, an alkyl group or an alkoxy group, or X and Y together represent an oxo group. The hydantoin derivatives significantly suppress the generation of arthritis and arteritis (cutaneous ulcer and auricular infarcted necrosis) which are naturally developed in model animals (MRL/lpr), and further significantly elongate the survival rate of MRL/lpr mice. Consequently, the hydantoin derivatives, having low toxicity and little side effects are very useful as highly safe therapeutic agents for intractable vasculitis such as malignant rheumatoid arthritis.

Inventors: Naiki; Mitsuru (Katoh-gun, JP), Numazawa; Takumi (Katoh-gun, JP), Okada; Tomoyuki (Katoh-gun, JP), Ienaga; Kazuharu (Katoh-gun, JP), Sawada; Kazuyoshi (Katoh-gun, JP)

Assignee: Nippon Zoki Pharmaceuticals Co., Ltd.

International Classification: A61K 31/4166 (20060101); A61K 31/4164 (20060101); A64K 031/415 ()

Expiration Date: 06/26/2018